More about Familial Medullary Thyroid Carcinoma
The treatment landscape for advanced and metastatic MTC changed dramatically with the arrival of selective RET inhibitors. Selpercatinib (Retevmo, Eli Lilly) received full FDA approval in September 2024 for advanced or metastatic RET-mutant MTC, demonstrating superior progression-free survival over older multikinase inhibitors.
Keep reading about Familial Medullary Thyroid Carcinoma
This selective agent has largely replaced the older multikinase inhibitors vandetanib (Caprelsa, approved 2011) and cabozantinib (Cometriq, Exelixis, approved 2012), which carry broader side-effect profiles due to their less targeted mechanism.
Pralsetinib (Gavreto), another selective RET inhibitor, previously held accelerated approval for RET-altered MTC but that indication was voluntarily withdrawn in 2023 when the required confirmatory trial proved infeasible.
The cancer characteristically presents with elevated serum calcitonin and carcinoembryonic antigen (CEA) that can be detected by screening before palpable disease develops. MTC can metastasize to lymph nodes, lungs, liver, and bones. Associated features in MEN 2A RET mutation carriers include pheochromocytoma (50% of MEN 2A families) and primary hyperparathyroidism (20-30% of MEN 2A families).
FMTC is primarily characterized by MTC alone, though families with certain cysteine codon RET mutations should still be screened for pheochromocytoma. Unlike sporadic MTC, hereditary MTC detected early through family screening and treated with prophylactic thyroidectomy in childhood has excellent prognosis (>95% 10-year survival if performed before calcitonin elevation).
What are the symptoms of Familial Medullary Thyroid Carcinoma?
These are common symptoms of Familial Medullary Thyroid Carcinoma, and how strong they are varies from person to person.
- Medullary thyroid carcinoma
- Elevated calcitonin levels
- Thyroid nodule or mass
- Metastatic disease with variable symptoms
- Diarrhea from calcitonin excess
- Associated MEN 2 features in some families
Who gets Familial Medullary Thyroid Carcinoma?
RET mutations show near-complete penetrance for medullary thyroid carcinoma by adulthood, with timing dependent on the specific codon mutation; earlier onset is common with more aggressive mutations. Affects males and females equally with no gender predominance. Autosomal dominant inheritance requires only one mutated copy from affected parent; approximately 50% of offspring inherit mutation.
Specific RET codon mutations (codons 634, 620, 611, 618, etc.) associate with varying disease severity and onset age. Genotype-phenotype correlations help predict disease aggressiveness. All populations affected; no ethnic or racial predisposition identified. Early-onset MTC common; some patients develop cancer in childhood if not screened and treated prophylactically.
Next steps: find trials you might fitsee approved treatmentsget help payingget alerts
Which medicines are FDA-approved for Familial Medullary Thyroid Carcinoma?
There are currently 3 FDA-approved medications for Familial Medullary Thyroid Carcinoma.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
How to get help paying for Familial Medullary Thyroid Carcinoma treatment
Charity funds and drugmaker programs for Familial Medullary Thyroid Carcinoma, checked at the source.
- From a charity · The Assistance FundThyroid Cancer fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
- Retevmo (Selpercatinib) · Retevmo Savings Card
- Caprelsa (Vandetanib) · CAPRELSA Access Support
- Cometriq (Cabozantinib) · Exelixis Access Services (EASE)
Every program and fund for Familial Medullary Thyroid Carcinoma, by insurance →
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for Familial Medullary Thyroid Carcinoma
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
The RET gene page lists every condition Orphanet links to the gene and the open trials that name it.
Finding labs...
Trusted Familial Medullary Thyroid Carcinoma resources
Reputable organizations and medical references for learning more about Familial Medullary Thyroid Carcinoma, including disease registries, foundation resources, and clinical guidelines.